Adagene Operating Income 2011-2026 | ADAG

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Adagene

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-21.4 M	-36 M	-23.7 M	-83.9 M	-72.4 M	-43.2 M	-19.2 M	-17.3 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-17.3 M	-83.9 M	-39.6 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Allakos ALLK	-196 M	-	-	$ 28.6 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
AlloVir ALVR	-46.2 M	-	4.14 %	$ 49.1 M	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	-33.3 M	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	231 M	$ 22.67	-	$ 3.76 B	USA
Applied Molecular Transport AMTI	-127 M	-	-	$ 10.1 M	USA
AIkido Pharma AIKI	-55.7 M	-	1.93 %	$ 17.4 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Galectin Therapeutics GALT	-20.1 M	$ 2.32	-	$ 148 M	USA
Greenwich LifeSciences GLSI	-16 M	$ 22.8	-	$ 297 M	USA
Genmab A/S GMAB	2.64 B	$ 26.79	-	$ 16.8 B	Danmark
Avenue Therapeutics ATXI	-3.08 M	-	-52.27 %	$ 4.45 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
AgeX Therapeutics AGE	-24 M	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	-70.8 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	-30 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	15.3 B	$ 102.06	-	$ 27.2 B	Germany
Brainstorm Cell Therapeutics BCLI	-9.95 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
Innoviva INVA	164 M	$ 23.69	-	$ 1.6 B	USA
Aquestive Therapeutics AQST	-71.1 M	$ 4.09	-	$ 437 M	USA
Arcutis Biotherapeutics ARQT	-12.2 M	$ 23.29	-	$ 2.96 B	USA
Jaguar Health JAGX	-45.9 M	$ 0.24	-	$ 560 K	USA
KalVista Pharmaceuticals KALV	-112 M	$ 19.24	-	$ 1.04 B	Britain
Autolus Therapeutics plc AUTL	-271 M	$ 1.48	-	$ 394 M	Britain
Kamada Ltd. KMDA	-696 K	$ 8.15	-	$ 260 M	Israel
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
AVROBIO AVRO	10.2 M	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	-9.95 M	$ 2.91	-	$ 4.79 M	Israel
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Evogene Ltd. EVGN	-31 M	$ 0.79	-0.65 %	$ 27.9 M	Israel